Genetic characterization of incident HIV type 1 subtype E and B strains from a prospective cohort of injecting drug users in Bangkok, Thailand

AIDS Research and Human Retroviruses

Volumn 16, Issue 8, 2000, Pages 699-707

  Subbarao, Shambavi ^a   Vanichseni, Suphak ^b   Hu, Dale J ^a   Kitayaporn, Dwip ^c,d   Choopanya, Kachit ^b   Raktham, Suwanee ^b   Young, Nancy L ^a,d   Wasi, Chantapong ^e   Sutthent, Ruengpung ^e   Luo, Chi Cheng ^a   Ramos, Artur ^a   Mastro, Timothy D ^a,d,f  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Bangkok Metropolitan Administration   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

^d HIV/AIDS Collaboration   (Thailand)

^e MAHIDOL UNIVERSITY   (Thailand)

^f MINISTRY OF PUBLIC HEALTH   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; VIRUS DNA; VIRUS PROTEIN;

ARTICLE; CONTROLLED STUDY; DRUG ABUSE; GENETIC DISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; STRAIN DIFFERENCE; SURFACE CHARGE; SYNCYTIUM; THAILAND; VIRUS CELL INTERACTION; VIRUS STRAIN;

AMINO ACID SEQUENCE; COHORT STUDIES; GLYCOSYLATION; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PHYLOGENY; PROSPECTIVE STUDIES; RECEPTORS, HIV; SEQUENCE ANALYSIS, DNA; SUBSTANCE ABUSE, INTRAVENOUS; THAILAND;

EID: 0034690623     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922200308693     Document Type: Article

References (49)

1. 1. Ou CY, Takebe Y, Luo CC, et al.: Wide distribution of two subtypes of HIV-1 in Thailand. AIDS Res Hum Retroviruses 1992;8:1471-1472.
2. 2. Ou CY, Takebe Y, Weniger BG, Luo CC, et al.: Independent introduction of the major HIV-1 genotypes into distinct high-risk populations in Thailand. Lancet 1993;341:1171-1174.
3. 3. McCutchan FE, Hegerich PA, Brennan TP, et al.: Genetic variants of HIV-1 in Thailand. AIDS Res Hum Retroviruses 1992; 11:1187-1895.
4. 4. Weniger B, Takebe Y, Ou CY, and Yamazaki S: The molecular epidemiology of HIV in Asia. AIDS 1994;8(Suppl. 2):S131-S141.
5. 5. Subbarao S and Schochetman G: Genetic variability of HIV-1. AIDS 1996;10(Suppl. A):S13-S23.
6. 6. Subbarao S, Limpakarjanarat K, Mastro TD, et al.: HIV type 1 in Thailand, 1994-1995: Persistence of two subtypes with low genetic diversity. AIDS Res Hum Retroviruses 1998;14:319-327.
7. 7. Weniger BG, Limpakarnjanarat K, Ungchusak K, et al.: The epidemiology of HIV infection and AIDS in Thailand. AIDS 199;5(Suppl. 2):S71-S85.
8. 8. Masto TD, Kitayaporn MD, Weniger BG, et al.: Estimating the number of HIV-infected injecting drug users in Bangkok: A capture-recapture method. Am J Public Health 1994;84:1094-1099.
9. 9. Kitayaporn D, Uneklabh C, Weniger BG, et al.: HIV-1 incidence determined retrospectively among drug users in Bangkok, Thailand. AIDS 1994;8:1443-1450.
10. 10. Wasi C, Herring B, Raktham S, Vanichseni S, et al.: Determination of HIV-1 subtypes in injecting drug users in Bangkok, Thailand, using peptide-binding enzyme immunoassay and heteroduplex mobility assay: Evidence of increasing infection with HIV-1 subtype E. AIDS 1995;9:843-849.
11. 11. Kalish ML, Baldwin A, Raktham S, Wasi C, et al.: The evolving molecular epidemiology of HIV-1 envelope subtypes in injecting drug users in Bangkok, Thailand: Implications for HIV vaccine trials. AIDS 1995;9:851-857.
12. 12. Choopany K, Vanichseni S, Des Jarlais DC, et al.: Risk factors and seropositivity among injecting drug users in Bangkok, Thailand. AIDS 1991;5:1509-1513.
13. 13. Vanichseni S, Choopanya K, Des Jarlais DC, et al.: HIV testing and sexual behavior among intravenous drug users in Bangkok, Thailand. J Acquir Immune Defic Syndr 1992;5:1119-1123.
14. 14. Wright NH, Vanichseni S, Akaresewi P, Wasi C, and Choopanya K: Was the 1988 HIV epidemic among Bangkok's injecting drug users a common source outbreak? AIDS 1994;8:529-532.
15. 15. Kitayaporn D, Vanichseni S, Mastro TD, et al.: Infection with HIV-1 subtypes B and E in injecting drug users screened for enrollment into a prospective cohort in Bangkok, Thailand. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19:289-295.
16. 16. Vanichseni S, Sonchai W, Plangsringarm K, Akarasewi P, Wright N, and Choopanya K: Second seroprevalence study among Bangkok's intravenous drug addicts (IVDA). In: Vth International Conference on AIDS, June 1989, Montreal, Canada. [Abstract TGO23]
17. 17. Vanichseni S, Plangsringarm K, Sonchai W, Akarasewi P, Wright N, and Choopanya K: Prevalence rate of primary HIV infection among drug users in narcotics clinics and rehabilitation center of Bangkok Metropolitan Administration in 1989. Thai AIDS J 1989;1:75-82.
18. 18. Uneklabh C, Phutiprawan T, and Uneklabh T: Prevalence of HIV infection among Thai drug dependents. In: IVth International Conference on AIDS, June 1988, Stockholm, Sweden. [Abstract 5524]
19. 19. Schochetman G, Subbarao S, and Kalish ML: Methods for studying genetic variation of the human immunodeficiency virus (HIV). In: Viral Genome Methods (Adolph KW, ed.). CRC Press, Boca Raton, Florida, 1996, pp. 25-41.
20. 20. Chen J, Young NL, Subbarao S, et al.: HIV type 1 subtypes in Guangxi Province, China. AIDS Res Hum Retroviruses 1999;15: 81-84.
21. 21. Kumar S, Tamura K, and Nei M: MEGA - Molecular Evolutionary Genetics Analysis, version 1.02. Institute of Molecular Evolutionary Genetics, The Pennsylvania State University, University Park, Pennsylvania, 1993.
22. 22. Efron B: The Jackknife, the Bootstrap and Other Resampling Plans. CBMS-NSF Regional Conference Series in Applied Mathematics, Monograph 38. SIAM, Philadelphia, Pennsylvania, 1982.
23. 23. Gurgo C, Guo HG, Franchini G, et al.: Envelope sequences of two new United States HIV-1 isolates. Virology 1988;164:531-536.
24. 24. Nakamura GR, Byrn R, Wilkes DM, et al.: Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies of the C4 domain of gp120 from human immunodeficiency virus type 1. Virol 1995;67:6179-6191.
25. 25. Berman PW, Gray AM, Wrin T, Vannari JC, et al.: Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers. J Infect Dis 1997;176:384-397.
26. 26. Choe H, Farzan M, Sun Y, et al.: The B-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996;85:1135-1148.
27. 27. Cocchi F, DeVico A, Garzino-Demo A, Cara A, Gallo RC, and Lusso P: The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine mediated blockade of infection. Nature Med 1996;2:1244-1247.
28. 28. Speck RF, Wehrly K, Platt EJ, et al.: Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop. J Virol 1997;71:7136-7139.
29. 29. Xiao L, Owen SM, Goldman I, Lal AA, deJong JJ, Goudsmit J, and Lal RB: CCR5 coreceptor usage of non-syncytium-inducing primary HIV-1 is independent of phylogenetically distinct global HIV-1 isolates: Delineation of consensus motif in the V3 domain that predicts CCR5 usage. Virology 1998;240:83-92.
30. 30. Dighe PK, Korbe BT, and Foley BT: Global variation in the HIV-1 V3 region. In: Human Retroviruses and AIDS. Los Alamos National Laboratory, Los Alamos, New Mexico, 1997, III-74-84.
31. 31. Korber B, Loussert-Ajaka, Blouin J, and Saragost S: A comparison of HIV-1 group M and group O functional and immunogenic domains in the gag p24 protein and the C2-V3 region of the envelope protein. In: HIV Molecular Immunology Database 1996 (Korber B, Brander C, Moore JP, and D'Souza PM, eds.). IV 61-IV 77.
32. 32. Chackerian B, Rudensey LM, and Overbaugh J: Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus that evolve in the host alter recognition by neutralizing antibodies. J Virol 1997;77: 7719-7727.
33. 33. Reitter JN, Means RE, and Desrosiers RC: A role for carbohydrates in immune evasion in AIDS. Nature Med 1998;4:679-684.
34. 34. Hu DJ, Buve A, Baggs J, van der Groen G, and Dondero TJ: What role does HIV-1 subtype play in transmission and pathogenesis? An epidemiological perspective. AIDS 1999;13:873-881.
35. 35. Fouchier RAM, Groenink M, Kootstra NA, et al.: Phenotype-associated sequence variation in the third variable region of the human immunodeficiency virus typel gp120 molecule. J Virol 1992;66:3183-3187.
36. 36. Hwang SS, Boyle TJ, Lyerly HK, and Cuellen BR: Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 1991;253:71-74.
37. 37. De Jong JJ, Goudsmit J, Keulen W, Klaver B, Krone W, Tersmette M, and De Ronde A: Human immunodeficiency viruses type 1 chimeric for the envelope V3 domain are distinct in syncytium formation and replication capacity. J Virol 1992;66:757-765.
38. 38. Chesebro B, Wehrly K, Nishio J, and Perryman S: Mapping of independent V3 envelope determinants of human immunodeficiency type 1 macrophage tropism and syncytium formation in lymphocytes. J Virol 1996;70:9055-9059.
39. 39. de Wolf F, Hogervorst E, Goudsmit J, Fenyö E, Rübsamen-Waigmann H, et al.: Syncytium inducing (SI) and non-syncytium inducing (NSI) capacity of human immunodeficiency virus type-1 (HIV-1) subtypes other than B: Phenotypic and genotypic characteristics. AIDS Res Hum Retroviruses 1994;10:1387-1400.
40. 40. Rübsamen-Waigmann H, von Briesen H, Holmes H, et al.: Standard conditions of virus isolation reveal biologic variability of HIV type 1 in different regions of the world. AIDS Res Hum Retroviruses 1994;11:1402-1408.
41. 41. Zhang L, Huang Y, He T, Cao Y, and Ho DD: HIV-1 subtype and second receptor. Nature (London) 1996;383:768.
42. 42. Zhu T, Mo H, Wang N, Nam DS, Cao Y, Koup R, and Ho DD: Genotypic and phenotypic characterization of HIV-1 in patients with primary infection. Science 1993:261:1179-1181.
43. 43. Zhang LQ, MacKenzie P, Cleland A, Holmes EC, Leigh Brown AJ, and Simmonds P: Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection. J Virol 1993;67:3345-3356.
44. 44. Van't Wout AB, Kootstra NA, Mulder-Kaminga GA, et al.: Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. J Clin Invest 1994;94:2060-2067.
45. 45. Yu XF, Wang Z, Vlahov D, Markham RB, Farzadegan H, and Margolick JB: Infection with dual-tropic human immunodeficiency virus type 1 variants associated with rapid total T cell decline and disease progression in injecting drug users. J Infect Dis 1998; 178:338-396.
46. 46. Goudsmit J, Lukashov V, Van Amelidjen EJC, Zorgdrager F, Van Den Burg R, and Cornelissen M: Impact of sexual versus parenteral transmission events on the evolution of the gag and env genes of HIV type 1. AIDS Res Hum Retroviruses 1998;14:1483-1486.
47. 47. Roos MT, Lange JMA, de Goede REY, Coutinho RA, Schellekens PTA, Miedema F, and Tersmette M: Viral phenotype and immune response in primary human immunodeficiency virus type 1 infection. J Infect Dis 1992;165:427-432.
48. 48. Menu E, Reynes J-M, Muller-Trutwin MC, et al.: Predominance of CCR5-dependent HIV-1 subtype E isolates in Cambodia. J Acquir Immune Defic Syndr Hum Retrovirology 1999;20:481-487.
49. 49. Mastro TD, Vanichseni S, Kitayporn D, et al.: Viral load and CD4/CD8 cell count in injecting drug users newly infected with HIV-1 subtypes B and E, Bangkok. In: 6th Conference on Retroviruses and Opportunistic Infections, 1990, Chicago, Illinois. [Abstract 275]